Ftse Mib
32.976,57
0,95%
DAX
18.087,30
0,37%
S&P 500
5.431,60
-0,04%
NASDAQ
17.688,88
0,12%
Bitcoin
66.221,89
-0,63%
Registration Strip Icon for default Registrati gratuitamente per ottenere quotazioni in tempo reale, grafici interattivi, flusso di opzioni in tempo reale e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Keros Therapeutics Inc (KROS) Keros Therapeutics Inc (KROS) Notizie

KROS

Keros Therapeutics (KROS)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:KROS
DataOraFonteTitoloSimboloCompagnia
04/06/202414:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KROSKeros Therapeutics Inc
04/06/202414:00GlobeNewswire Inc.Keros Therapeutics to Host a Corporate Update Conference Call and WebcastNASDAQ:KROSKeros Therapeutics Inc
03/06/202422:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KROSKeros Therapeutics Inc
03/06/202414:00GlobeNewswire Inc.Keros Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare ConferenceNASDAQ:KROSKeros Therapeutics Inc
28/05/202422:01GlobeNewswire Inc.Keros Therapeutics Appoints Jean-Jacques Bienaimé to its Board of DirectorsNASDAQ:KROSKeros Therapeutics Inc
14/05/202416:00GlobeNewswire Inc.Keros Therapeutics to Present at the 29th Annual Congress of the European Hematology AssociationNASDAQ:KROSKeros Therapeutics Inc
08/05/202414:03Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:KROSKeros Therapeutics Inc
08/05/202414:00GlobeNewswire Inc.Keros Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial ResultsNASDAQ:KROSKeros Therapeutics Inc
14/03/202413:00GlobeNewswire Inc.Keros Therapeutics Announces U.S. FDA Fast Track Designation for KER-050 in Lower-Risk Myelodysplastic SyndromesNASDAQ:KROSKeros Therapeutics Inc
05/03/202414:00GlobeNewswire Inc.Keros Therapeutics to Present at Leerink Partners 2024 Global Biopharma ConferenceNASDAQ:KROSKeros Therapeutics Inc
28/02/202422:01GlobeNewswire Inc.Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:KROSKeros Therapeutics Inc
29/01/202414:00GlobeNewswire Inc.Keros Therapeutics To Present at Pulmonary Vascular Research Institute 2024 Annual CongressNASDAQ:KROSKeros Therapeutics Inc
09/01/202414:00GlobeNewswire Inc.Keros Therapeutics Announces Closing of Upsized Public Offering of Common StockNASDAQ:KROSKeros Therapeutics Inc
04/01/202422:04Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:KROSKeros Therapeutics Inc
04/01/202422:02Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:KROSKeros Therapeutics Inc
04/01/202403:29GlobeNewswire Inc.Keros Therapeutics Announces Pricing of Upsized Public Offering of Common StockNASDAQ:KROSKeros Therapeutics Inc
03/01/202422:05GlobeNewswire Inc.Keros Therapeutics Announces Proposed Public Offering of Common StockNASDAQ:KROSKeros Therapeutics Inc
11/12/202312:00GlobeNewswire Inc.Keros Therapeutics Presents Clinical Data from its KER-050 Program at the 65th American Society of Hematology Annual Meeting and ExpositionNASDAQ:KROSKeros Therapeutics Inc
07/11/202314:00GlobeNewswire Inc.Keros Therapeutics to Present at Upcoming Healthcare ConferencesNASDAQ:KROSKeros Therapeutics Inc
06/11/202314:00GlobeNewswire Inc.Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2023 Financial ResultsNASDAQ:KROSKeros Therapeutics Inc
02/11/202314:00GlobeNewswire Inc.Keros Therapeutics to Present at the 65th American Society of Hematology Annual Meeting and ExpositionNASDAQ:KROSKeros Therapeutics Inc
04/10/202314:00GlobeNewswire Inc.Keros Therapeutics Presents Preclinical Data from its KER-065 Program at the 28th International Annual Congress of the World Muscle SocietyNASDAQ:KROSKeros Therapeutics Inc
07/08/202314:00GlobeNewswire Inc.Keros Therapeutics Reports Recent Business Highlights and Second Quarter 2023 Financial ResultsNASDAQ:KROSKeros Therapeutics Inc
27/07/202322:01GlobeNewswire Inc.Corrected: Keros Therapeutics to Host Conference Call and Webcast to Provide an Overview of TROPOS, the KER-012 Phase 2 Clinical Trial in Patients with Pulmonary Arterial HypertensionNASDAQ:KROSKeros Therapeutics Inc
24/07/202314:00GlobeNewswire Inc.Keros Therapeutics to Host Conference Call and Webcast to Provide an Overview of TROPOS, the KER-012 Phase 2 Clinical Trial in Patients with Pulmonary Arterial HypertensionNASDAQ:KROSKeros Therapeutics Inc
12/06/202323:33Edgar (US Regulatory)Report of Proposed Sale of Securities (144)NASDAQ:KROSKeros Therapeutics Inc
12/06/202322:14Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:KROSKeros Therapeutics Inc
12/06/202314:00GlobeNewswire Inc.Keros Therapeutics Announces Update to Participation at the Goldman Sachs 44th Annual Global Healthcare ConferenceNASDAQ:KROSKeros Therapeutics Inc
09/06/202312:04Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:KROSKeros Therapeutics Inc
09/06/202312:00GlobeNewswire Inc.Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from its KER-050 Program and Preclinical Data from its ALK2 Inhibitor Program at the 28th Annual Congress of the European Hematology AssociationNASDAQ:KROSKeros Therapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:KROS

La tua Cronologia

BIT
UCG
Unicredit
BIT
ISP
Intesa Sanpaolo
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
STLAM
Stellantis NV
BIT
ENI
Eni
BIT
BPE
Bper Banca
BIT
LDO
Leonardo
BIT
ENEL
Enel
BIT
BAMI
Banco BPM
BIT
RACE
Ferrari NV
BIT
STMMI
ST Microelectronics
BIT
TIT
Telecom Italia
BIT
NEXI
Nexi S.p.A
BIT
G
Generali
BIT
ERG
ERG
BIT
SRG
Snam
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network